COVID-19 Vaccination Strategies Should Consider Infection Risk in CAR T-cell Therapy Recipients
Muhammad Bilal Abid, MD, MRCP, discusses findings from a study outlining what is known about the risk of infections with CAR T-cell therapy and determinants of SARS-CoV-2 responses.
Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
October 21st 2021Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.
COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients
October 28th 2021Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.
Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination
Muhammad Bilal Abid, MD, discusses immune-compromising factors that are indigenous to CAR T-cell recipients, the immunogenic potential of different COVID-19 vaccines, determinants of response, and the potential need for booster strategies.
